Table 1.

Clinical and demographic information for the three groups

	LTLE	RTLE	Controls
N	21	23	28
Age	42.5 ± 13.6	36.4 ± 14.5	39.3 ± 13.3
Gender F/M	15/7	10/13	21/7
Intracranial volume (L)	1.35 ± 0.23	1.48 ± 0.27	1.52 ± 0.18
Edinburgh handedness	87 ± 44	78 ± 57	76 ± 53
W/o right arcuate	13/8	19/4	25/3
Full‐scale IQ	91 ± 13.8	96 ± 10.4	n/a
Age at epilepsy onset	19 ± 16.1	22 ± 12.1	n/a
Duration of epilepsy	24 ± 19.1	15 ± 12.3	n/a
Seizure types (no. of patients)	13—CPS only	12—CPS only
	2—CPS + GTCS	4—CPS + GTCS
	1—SPS only	0—SPS only
	1—CPS w/2° GTCS	3—CPS w/2° GTCS
	3—CPS + SPS	3—CPS + SPS
	0—CPS w/2° GTCS + SPS	1—CPS w/2° GTCS + SPS
MTS/non‐MTS (no. of patients)	11/10	9/14	n/a
Surgery	14 (67%)	14 (61%)
	12—ATL	14—ATL
	1—laser ablation
	1—gamma knife
Seizure‐free post‐surgery	12 (86%)	9 (64%)
	Range, 14–72 months	Range, 8–48 months
	Post‐op	Post‐op	n/a
Medication (no. of patients)	4—Carbamazepine	4—Carbamazepine
	1—Depakote	3—Depakote	n/a
	2—Lacosamide	5—Lacosamide
	7—Lamotrigine	4—Lamotrigine
	10—Levetiracet.	12—Levetiracet.
	1—Oxcarbazepine	4—Oxcarbazepine
	2—Phenobarbital	1—Phenobarbital
	3—Topiramate	3—Topiramate
	2—Zonisamide	3—Zonisamide
	5—Other	6—Other

Abbreviations: MTS, mesial temporal sclerosis; CPS, complex partial seizures; GTCS, generalized tonic‐clinic seizures; SPS, simple partial seizures; and w/2° GTCS, with secondary generalization.